Jim Weatherall, Head of Data Science and AI at AstraZeneca talks to Citi&rsquo;s Adam Spielman about how AI will impact Biopharma, and how big pharma companies and small biotechs alike need to adapt.

The Future of Health: how AI will transform Biopharma

Download Report

The average global citizen born today will live almost 30 years longer than one of their forebears born in 1950, one of humanity&rsquo;s most astonishing achievements.
But the global healthcare system&rsquo;s vital signs have deteriorated recently. Life expectancy in many western countries has stalled over the past 15 years, worsening through the pandemic. And a shocking rise in population obesity and an expected rapid increase in dementia is storing up future pain.
A rapidly aging population is already driving healthcare system costs to potentially unsustainable levels, and in many advanced economies the cost of healthcare as a proportion of GDP has more than doubled in the past 30 years.
<img src="/rcs/v1/media/citigpa/akpublic/storage/retrieveMediaFile/664b45d77efdbd75e99fa209" alt="" width="800" height="403">
The Oxford Prescription draws on the insights and expertise of 17 leading Oxford University professors, looking at ways in which global healthcare can be improved, examining population health, the balance between primary and secondary care, and how new data and technologies could revolutionize the delivery of healthcare.
The fact is healthcare today still largely works by treating problems after symptoms become serious. The core of The Oxford Prescription is to use newly developed techniques to address medical issues as early as possible, not after symptoms appear.
The science behind these techniques &mdash; like polygenic risk scoring and liquid biopsies &mdash; is not 100% settled. But things look promising.
The Oxford Prescription demands a significant reorganization of healthcare delivery and drug development, as well as better use of digital technologies. It also calls for more aggressive use of public health measures.
The basic tenets of The Oxford Prescription are:
<ul>
<li>Address medical issues as early as possible</li>
<li>Reorganize how healthcare is delivered</li>
<li>Leverage digital technology</li>
<li>Focus drug development on large populations</li>
<li>More aggressive public health measures, particularly on obesity</li>
<li>Ensure we&rsquo;re prepared for future outbreaks and pandemics</li>
</ul>
The Oxford Prescription does not rely on major new breakthroughs: it is mostly about applying and developing what we already know. That said, major developments in medicine are likely in the coming decades &mdash; there&rsquo;s no reason to expect science and progress to stall.
The report covers a huge range of topics, from drug discovery to biomedical engineering, public health and nutrition to genetic studies, immunology to tropical &amp; infectious diseases, and much more. It is essential reading for anyone interested in the future of the global healthcare system.
To read the full report,&nbsp;<a style="box-sizing: border-box; color: rgb(37, 91, 227); text-decoration-line: underline; cursor: pointer; transition: color 0.2s cubic-bezier(0.6, 0, 1, 1) 0s; font-family: Citi-Sans-Text-Regular; font-size: 18px; white-space: normal; background-color: rgb(255, 255, 255);" href="https://ir.citi.com/gps/MNKTSpX7j6trP%2BkGcP9kqDMkSszK%2BxtCXnx3j8SvywFATgD4bT%2B4eaGFqrzUBB%2B7" target="_blank" rel="noopener" data-link-source="tiny">click here.</a>
&nbsp;

The Oxford Prescription

The average global citizen born today will live almost 30 years longer than one of their forebears born in 1950, one of humanity&rsquo;s most astonishing achievements.

Future of Healthcare

Citi&rsquo;s Adam Spielman, Head of Health, Citi Global Insights, with Rory Collins, Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology and John Todd, Professor of Precision Medicine and Director of the Centre for Human Genetics (CHG) discuss how the faculty at the University of Oxford believe healthcare can be improved.

Future of Healthcare: The Oxford Prescription

Global Insights

Adam Spielman, Head of Health, Citi Global Insights with &nbsp;Michael Farrell, CEO at ResMed and Carlos Nunez, CMO,&nbsp; discuss the impact of GLP-1s on Sleep Apnea companies.
Key topics:
<ul type="disc">
<li style="font-size: 16px;">How do sleep apnea patients who use GLP-1s behave differently from non-users?</li>
<li style="font-size: 16px;">How does this affect companies providing solutions for obstructive sleep apnea</li>
<li style="font-size: 16px;">To what extent is ResMed changing its strategy because of GLP-1s?</li>
<li style="font-size: 16px;">If GLP-1s do reduce obesity long term, what impact would there be?</li>
</ul>

Adam Spielman, Head of Health, Citi Global Insights with &nbsp;Michael Farrell, CEO at ResMed and Carlos Nunez, CMO,&nbsp; discuss the impact of GLP-1s on Sleep Apnea companies.
&nbsp;

Future of Healthcare & Wellness: The Impact of GLP-1s on Sleep Apnea

Adam Spielman, Head of Health, Citi Global Insights with Prashant Agrawal, Founder and CEO at Impact Analytics discuss GLP-1&rsquo;s impact on apparel retail.
Key topics:
<ul type="disc">
<li style="font-size: 16px;">If GLP-1s do reduce obesity long term, what impact would there be on apparel retailers?</li>
<li style="font-size: 16px;">How much evidence is there that GLP-1s are already having an impact?</li>
<li style="font-size: 16px;">How do retailers need to adapt? Are margins likely to be affected?</li>
<li style="font-size: 16px;">To what extent are retailers changing their strategy because of GLP-1s?</li>
</ul>

Adam Spielman, Head of Health, Citi Global Insights with Prashant Agrawal, Founder and CEO at Impact Analytics discuss GLP-1&rsquo;s impact on apparel retail.